. 2021 Sep 16;11:18479. doi: 10.1038/s41598-021-97408-y

Table 2.

Characteristics of Patients with Graves Disease. TSI thyroid stimulating immunoglobulins.

ID	Age	Gender	Laboratory Tests	I-123 Uptake	I-123 Scan
Patient 1	51	Female	T3 (Triiodothyronine) 3.69 (0.8–2.0) TSH < 0.01 (0.36–3.74) Free T4 2.0 (0.8–1.5) TSI > 700 (< 140% baseline)	61%(4 h)	Diffuse homogenous uptake without focal nodularity (Fig. 1a)
Patient 2	45	Female	T3 (Triiodothyronine) 6.5 (0.8–2.0) TSH < 0.01 (0.36–3.74) Free T4 8.0(0.8–1.5) TSI > 639 (< 140% baseline)	6-h uptake- 90.6% 24-h uptake—66.3%	Diffuse radiotracer uptake in the thyroid gland (Fig. 2a)

Age

Gender

Laboratory Tests

I-123 Uptake

I-123 Scan

Patient 1

Female

T3 (Triiodothyronine) 3.69 (0.8–2.0)

TSH < 0.01 (0.36–3.74)

Free T4 2.0 (0.8–1.5)

TSI > 700

(< 140% baseline)

61%(4 h)

Diffuse homogenous uptake without focal nodularity (Fig. 1a)

Patient 2

Female

T3 (Triiodothyronine) 6.5 (0.8–2.0)

TSH < 0.01 (0.36–3.74)

Free T4 8.0(0.8–1.5)

TSI > 639

(< 140% baseline)

6-h uptake- 90.6%

24-h uptake—66.3%

Diffuse radiotracer uptake in the thyroid gland (Fig. 2a)